Totally Endoscopic Ablation of Atrial Fibrillation

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective To evaluate the efficiency of totally endoscopic ablation of AF compared to rate control management of AF.

Secondary Objectives

Does totally endoscopic ablation:

• reduce atrial fibrillation symptoms?

• increase working capacity and improve quality of life?

• improve atrial function?

• reduce the risk for stroke?

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Region Örebro County
• Collaborator: Medtronic

Criteria

Inclusion Criteria:

1. Age > 50 years

2. Longstanding persistent AF of > 1 year duration

3. Severe symptoms related to AF

4. Have signed and dated Informed Consent.

5. Willing and able to comply with the protocol for the duration of the trial.

Exclusion Criteria:

1. Severe ischemic heart disease or heart valve disease

2. Thrombus formation in left atrial appendage

3. Intolerance to warfarin medication

4. Advanced pulmonary disease, FEV 1 < 1.5 litre

5. Left atrial diameter > 60 mm

6. Body Mass Index (BMI) > 35 kg/m2

7. Previous pulmonary or heart surgery

8. Participation in another clinical trial within the last 30 days prior to enrollment